The creation of accelerators of technological research (ART) is a priority of Inserm’s strategic plan. On October 12, 2017, Inserm has launched its second ART, this time devoted to 3D Bioprinting, in Bordeaux. It is the only tech unit to use the three principal 3D biological printing technologies: laser, ink jet and micro-extrusion. Within the ART, researchers and engineers work together to as quickly as possible transform the fruits of research into technological innovation.
A true pioneer, Inserm is one of the first research institutes to venture into 3D bioprinting. The Inserm’s BioPrint ART, located in the BioTis Joint Research Unit (Inserm/Université de Bordeaux), aims to apply its knowledge to various domains, such as tissue engineering, oncology or pharmacology, in order to succeed in creating tissues and complex organoids in the near future.
The ultimate aim of the BioPrint ART is to develop a structure for training and 3D printing biomanufacture, for use by Inserm’s various laboratories. This new organizational model represents technological progress at the service of fundamental research and the pharmaceutical industry.